-
Sleep Medicine Clinics Jun 2019The term "acute insomnia" has been part of the language of sleep medicine since the late 1970s. Despite that, a comprehensive research agenda on the topic has only... (Review)
Review
The term "acute insomnia" has been part of the language of sleep medicine since the late 1970s. Despite that, a comprehensive research agenda on the topic has only recently been advanced. This has prevented a clinical viewpoint on the assessment and management of acute insomnia. Although there is a cognitive behavioral therapy for insomnia focused intervention, designed to circumvent the transition from acute insomnia to insomnia disorder, the results from trials undertaken have been variable and limited by small sample sizes. There is much work to be done regarding the assessment, diagnosis, and management of acute insomnia.
Topics: Acute Disease; Cognitive Behavioral Therapy; Humans; Sleep Initiation and Maintenance Disorders
PubMed: 31029192
DOI: 10.1016/j.jsmc.2019.01.007 -
Journal of UOEH 2019There have been no reviews describing the efficacy of the combination of both rehabilitation and nutritional treatments. This systematic review aimed to assess the... (Review)
Review
There have been no reviews describing the efficacy of the combination of both rehabilitation and nutritional treatments. This systematic review aimed to assess the effects of nutritional therapy on patients with an acute and critical illness undergoing rehabilitation. Online searches using PubMed (MEDLINE), Cochrane Central Register of Controlled Trials, EMBASE (ELSEVIER), and Ichu-shi Web databases identified 986 articles, and 16 additional articles were found through other sources. Each trial assessed for the risk of bias using the Cochrane Collaboration's tool, and the quality of the body of evidence with The Grading of Recommendations Assessment, Development and Evaluation approach. Two randomized controlled trials were included in this review. Jones et al reported that with an enhanced rehabilitation program, there was no effect of nutritional intervention on quality of life (standardized mean difference [SMD] 0.55, 95% confidence intervals [CI] -0.05 to 1.15; P = 0.12). However, Hegerova et al reported positive effects of physical therapy and oral supplements on muscle mass (0.65; 95% CI, 0.36 to 0.93; P < 0.00001) and activities of daily living (SMD 0.28, 95% CI 0.00 to 0.56; P = 0.05). Strengthened nutritional intervention with enhanced rehabilitation treatment for patients with acute and critical illness may possibly be effective for increasing muscle mass, as well as for improving activities of daily living within a short period after discharge.
Topics: Activities of Daily Living; Acute Disease; Critical Illness; Humans; Nutrition Therapy; Physical Therapy Modalities; Quality of Life
PubMed: 31548485
DOI: 10.7888/juoeh.41.303 -
Clinical Chemistry Dec 2018
Topics: Acute Disease; Hemolysis; Humans; Leukemia
PubMed: 30487189
DOI: 10.1373/clinchem.2018.290536 -
Psychosomatics 2015Findings from physical disease resilience research may be used to develop approaches to reduce the burden of disease. However, there is no consensus on the definition... (Review)
Review
BACKGROUND
Findings from physical disease resilience research may be used to develop approaches to reduce the burden of disease. However, there is no consensus on the definition and measurement of resilience in the context of physical disease.
OBJECTIVE
The aim was to summarize the range of definitions of physical disease resilience and the approaches taken to study it in studies examining physical disease and its relationship to resilient outcomes.
METHODS
Electronic databases were searched from inception to March 2013 for studies in which physical disease was assessed for its association with resilient outcomes. Article screening, data extraction, and quality assessment were carried out independently by 2 reviewers, with disagreements being resolved by a third reviewer. The results were combined using a narrative technique.
RESULTS
Of 2280 articles, 12 met the inclusion criteria. Of these studies, 1 was of high quality, 9 were of moderate quality, and 2 were low quality. The common findings were that resilience involves maintaining healthy levels of functioning following adversity and that it is a dynamic process not a personality trait. Studies either assessed resilience based on observed outcomes or via resilience measurement scales. They either considered physical disease as an adversity leading to resilience or as a variable modifying the relationship between adversity and resilience.
CONCLUSION
This work begins building consensus as to the approach to take when defining and measuring physical disease resilience. Resilience should be considered as a dynamic process that varies across the life-course and across different domains, therefore the choice of a resilience measure should reflect this.
Topics: Acute Disease; Chronic Disease; Humans; Resilience, Psychological
PubMed: 25620566
DOI: 10.1016/j.psym.2014.10.005 -
American Journal of Health-system... Mar 2021
Topics: Acute Disease; Heart Failure; Humans
PubMed: 33637976
DOI: 10.1093/ajhp/zxaa441 -
The Australian Journal of Rural Health Feb 2020To determine the incidence, clinical presentation and progress of acute post-streptococcal glomerulonephritis in Central Australia. (Observational Study)
Observational Study
OBJECTIVE
To determine the incidence, clinical presentation and progress of acute post-streptococcal glomerulonephritis in Central Australia.
DESIGN
Retrospective observational analysis.
SETTING
Paediatric inpatient admission at Alice Springs Hospital.
PARTICIPANTS
Patients admitted to Alice Springs Hospital under 14 years of age meeting diagnostic criteria for acute post-streptococcal glomerulonephritis between January 2010 and December 2014.
MAIN OUTCOME MEASURES
Incidence of acute post-streptococcal glomerulonephritis in central Australia. Biochemical abnormalities associated with acute post-streptococcal glomerulonephritis. Co-occuring conditions.
RESULTS
Sixty-nine out of the 174 cases reviewed were identified as having either acute post-streptococcal glomerulonephritis (63) or probable acute post-streptococcal glomerulonephritis (6). We calculate the incidence of APSGN admission to be higher than previously reported and the highest reported incidence globally in children. Clinical evidence of skin infection was frequently documented. Co-occurring infections were common, including scabies/head lice, urinary tract infection and pneumonia. Fifty-three patients showed biochemical evidence of acute kidney injury.
CONCLUSIONS
Aboriginal children in Central Australia have the highest incidence of acute post-streptococcal glomerulonephritis reported worldwide. Urgent action is required to improve housing and reduce overcrowding in Central Australian towns and communities to reduce the burden of disease of skin infection and Group A Streptococcus related diseases. Without effective change in living conditions, it is unlikely that there will be a significant change in the morbidity related to these conditions.
Topics: Acute Disease; Adolescent; Australia; Child; Child, Preschool; Female; Glomerulonephritis; Humans; Incidence; Infant; Infant, Newborn; Male; Retrospective Studies; Streptococcal Infections
PubMed: 31659821
DOI: 10.1111/ajr.12568 -
The Journal of the American Osteopathic... Nov 2020
Topics: Acute Disease; Diagnosis, Differential; Humans; Thyroiditis, Suppurative
PubMed: 32961559
DOI: 10.7556/jaoa.2020.132 -
British Journal of Pharmacology Jan 2018The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications.... (Review)
Review
UNLABELLED
The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors.
LINKED ARTICLES
This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.
Topics: Acute Disease; Animals; Chronic Disease; Drug Repositioning; Humans; Poly(ADP-ribose) Polymerase Inhibitors
PubMed: 28213892
DOI: 10.1111/bph.13748 -
MMW Fortschritte Der Medizin Feb 2022
Review
Topics: Acute Disease; Humans; Laboratories; Porphyria, Acute Intermittent
PubMed: 35146707
DOI: 10.1007/s15006-021-0666-1 -
Oral Diseases Jul 2021
Topics: Acute Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans
PubMed: 32931619
DOI: 10.1111/odi.13642